<DOC>
	<DOCNO>NCT01496131</DOCNO>
	<brief_summary>This study examine tecemotide ( L-BLP25 ) combination standard treatment prostate cancer .</brief_summary>
	<brief_title>Tecemotide ( L-BLP25 ) Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Histopathologic documentation prostate cancer confirm institution study enrollment prior start study Newly diagnose previously untreated prostate cancer intermediate high risk feature define protocol No evidence metastatic disease compute tomography ( CT ) / magnetic resonance imaging ( MRI ) bone scan No systemic steroid use within 2 week prior initiation experimental therapy . Limited dos systemic steroid prevent intravenous contrast , allergic reaction anaphylaxis ( subject know contrast allergy ) allow Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Human leukocyte antigen ( HLA ) A2 A3 positive immunologic monitor Hematological biochemical eligibility parameter define protocol No active malignancy within past 3 year ( exception nonmelanoma skin cancer carcinoma situ bladder ) Willing travel study center ( ) followup visit Age great equal 18 year old Able understand sign inform consent Must agree use effective birth control ( condom ) abstinence period 4 month last administration immunotherapy No evidence immunocompromised human immunodeficiency virus , medical condition require systemic steroid , medical condition require immunosuppressive therapy , splenectomy Active Hepatitis B Hepatitis C Subjects autoimmune disease require treatment specify protocol History immunodeficiency disease , hereditary congenital immunodeficiency Serious intercurrent medical illness A clinically significant cardiac disease Subjects receive prior therapy prostate cancer Subjects know brain metastasis , history seizure , encephalitis , multiple sclerosis Subjects receive investigational agent Contraindication biopsy bleed disorder , ratio prothrombin time partial thromboplastin time ( PT/PTT ) &gt; =1.5 time upper limit normal , artificial heart valve Contraindication MRI subject weigh &gt; 136 kilogram , allergy magnetic resonance ( MR ) contrast agent , subject pacemaker , cerebral aneurysm clip , shrapnel injury implantable electronic device Contraindication radiation therapy preexist active prostatitis proctitis , inflammatory bowel disease know genetic sensitivity ionizing radiation , history prior radiation pelvis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Tecemotide</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Goserelin</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>